Sandbox 781

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (20:50, 17 January 2020) (edit) (undo)
 
Line 1: Line 1:
=Crystal structure of MraY bound to carbacaprazamycin, 6OYH =
=Crystal structure of MraY bound to carbacaprazamycin, 6OYH =
-
<StructureSection load='6OYH' size='340' side='right' caption='Crystal structure of two MraY dimers'>
+
<StructureSection load='<scene name='61/612822/Asymmetric_unit/1'>asymmetric unit</scene> ((6OYH))' size='340' side='right' caption='Crystal structure of two MraY dimers'>
Line 22: Line 22:
== Asymmetric and biological unit ==
== Asymmetric and biological unit ==
-
The basal 3D scene shown on this page corresponds to the asymmetric unit, which contains 4 biological units of MraYAA (colors), which each of them is fused with the NB7 nanobody (teal). Mashalidis EH, Kaeser Bet al. , who solved this 3D structure, were screening antibodies. They determine that the presence of NB7 does not affect MraYAA enzymatic activity or inhibition by carbacaprazamycin <ref name="seven"/>.
+
The basal 3D scene shown on this page corresponds to the <scene name='61/612822/Asymmetric_unit/1'>asymmetric unit</scene>, which contains 4 biological units of MraYAA (colors), which each of them is fused with the NB7 nanobody (teal). Mashalidis EH, Kaeser Bet al. , who solved this 3D structure, were screening antibodies. They determine that the presence of NB7 does not affect MraYAA enzymatic activity or inhibition by carbacaprazamycin <ref name="seven"/>.
== MraY-Carbacaprazamycin structure ==
== MraY-Carbacaprazamycin structure ==

Current revision

Crystal structure of MraY bound to carbacaprazamycin, 6OYH

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 Hering J, Dunevall E, Ek M, Branden G. Structural basis for selective inhibition of antibacterial target MraY, a membrane-bound enzyme involved in peptidoglycan synthesis. Drug Discov Today. 2018 Jul;23(7):1426-1435. doi: 10.1016/j.drudis.2018.05.020., Epub 2018 May 18. PMID:29778697 doi:http://dx.doi.org/10.1016/j.drudis.2018.05.020
  2. 2.0 2.1 Koppermann S, Ducho C. Natural Products at Work: Structural Insights into Inhibition of the Bacterial Membrane Protein MraY. Angew Chem Int Ed Engl. 2016 Sep 19;55(39):11722-4. doi: 10.1002/anie.201606396. , Epub 2016 Aug 11. PMID:27511599 doi:http://dx.doi.org/10.1002/anie.201606396
  3. 3.0 3.1 3.2 3.3 Chung BC, Zhao J, Gillespie RA, Kwon DY, Guan Z, Hong J, Zhou P, Lee SY. Crystal structure of MraY, an essential membrane enzyme for bacterial cell wall synthesis. Science. 2013 Aug 30;341(6149):1012-6. doi: 10.1126/science.1236501. PMID:23990562 doi:10.1126/science.1236501
  4. 4.0 4.1 Koppermann S, Cui Z, Fischer PD, Wang X, Ludwig J, Thorson JS, Van Lanen SG, Ducho C. Insights into the Target Interaction of Naturally Occurring Muraymycin Nucleoside Antibiotics. ChemMedChem. 2018 Apr 23;13(8):779-784. doi: 10.1002/cmdc.201700793. Epub 2018, Mar 23. PMID:29438582 doi:http://dx.doi.org/10.1002/cmdc.201700793
  5. 5.0 5.1 Ichikawa S, Yamaguchi M, Hsuan LS, Kato Y, Matsuda A. Carbacaprazamycins: Chemically Stable Analogues of the Caprazamycin Nucleoside Antibiotics. ACS Infect Dis. 2015 Apr 10;1(4):151-6. doi: 10.1021/id5000376. Epub 2015 Feb 19. PMID:27622529 doi:http://dx.doi.org/10.1021/id5000376
  6. 6.0 6.1 6.2 6.3 Mashalidis EH, Kaeser B, Terasawa Y, Katsuyama A, Kwon DY, Lee K, Hong J, Ichikawa S, Lee SY. Chemical logic of MraY inhibition by antibacterial nucleoside natural products. Nat Commun. 2019 Jul 2;10(1):2917. doi: 10.1038/s41467-019-10957-9. PMID:31266949 doi:http://dx.doi.org/10.1038/s41467-019-10957-9
  7. 7.0 7.1 Winn M, Goss RJ, Kimura K, Bugg TD. Antimicrobial nucleoside antibiotics targeting cell wall assembly: recent advances in structure-function studies and nucleoside biosynthesis. Nat Prod Rep. 2010 Feb;27(2):279-304. doi: 10.1039/b816215h. Epub 2009 Dec 16. PMID:20111805 doi:http://dx.doi.org/10.1039/b816215h
  8. Romaniuk JA, Cegelski L. Bacterial cell wall composition and the influence of antibiotics by cell-wall and whole-cell NMR. Philos Trans R Soc Lond B Biol Sci. 2015 Oct 5;370(1679). pii: rstb.2015.0024., doi: 10.1098/rstb.2015.0024. PMID:26370936 doi:http://dx.doi.org/10.1098/rstb.2015.0024
  9. Bouhss A, Trunkfield AE, Bugg TD, Mengin-Lecreulx D. The biosynthesis of peptidoglycan lipid-linked intermediates. FEMS Microbiol Rev. 2008 Mar;32(2):208-33. doi: 10.1111/j.1574-6976.2007.00089.x., Epub 2007 Dec 10. PMID:18081839 doi:http://dx.doi.org/10.1111/j.1574-6976.2007.00089.x
  10. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, Nisar MA, Alvi RF, Aslam MA, Qamar MU, Salamat MKF, Baloch Z. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018 Oct 10;11:1645-1658. doi: 10.2147/IDR.S173867., eCollection 2018. PMID:30349322 doi:http://dx.doi.org/10.2147/IDR.S173867
Personal tools